Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

TGR-1202/Ibrutinib Combo Feasible, Highly Active for CLL/MCL

December 5th 2016

The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

After 5 Years of Follow-Up, Ibrutinib Continues to Impress in CLL/SLL

December 5th 2016

Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.

Lenalidomide Maintenance Improves PFS in High-Risk CLL

December 5th 2016

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.

Dr. Tam on Trials Investigating BGB-3111 in CLL and Waldenstrom's Macroglobulinemia

December 4th 2016

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

Acalabrutinib Monotherapy Effective for Richter Transformation

December 4th 2016

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Nivolumab/Ibrutinib Combo Shows Promise for Richter Transformation

December 3rd 2016

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Dr. Wierda on Factors to Consider in Frontline Management of CLL

December 1st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses factors that physicians should take into account when administering frontline treatment options to patients with chronic lymphocytic leukemia.

June's Quest to Develop Gene Therapies Is a Neverending Research Story

November 30th 2016

As with software upgrades, Carl H. June, MD, sees his work in cancer research as a job with ever-evolving updates.

CLL Landscape to Change Dramatically Over Next Decade

November 21st 2016

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

CHMP Issues Positive Opinion for Ofatumumab Combo in Relapsed CLL

November 12th 2016

The Committee for Medicinal Products for Human Use has recommended approval of ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia.

Dr. Brown on Recent Progress in the Treatment Landscape of CLL

November 8th 2016

Jennifer R. Brown, MD, PhD, Director, CLL Center, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the recent progress seen in the treatment landscape of chronic lymphocytic leukemia (CLL), and what still needs to be accomplished going forward.

Dr. Ferrajoli on Remaining Challenges in Treatment of CLL

November 2nd 2016

Alessandra Ferrajoli, MD, a professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the challenges that still remain in patients with chronic lymphocytic leukemia.

Dr. Wierda on Frontline Management of Patients With CLL

October 31st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of patients with chronic lymphocytic leukemia (CLL) in the firstline setting.

Frontline CLL Paradigm Rapidly Evolving to Include Novel Therapies

October 27th 2016

As more agents are approved in the treatment paradigm of chronic lymphocytic leukemia, researchers are exploring frontline options—in addition to ibrutinib and the regimen of fludarabine, cyclophosphamide, and rituximab—in ongoing trials.

Dr. Leis on Advances in CLL

October 26th 2016

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses treatment-related advances in the field of chronic lymphocytic leukemia (CLL) over the last several decades in an interview during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Secondary Malignancies a Challenge With CLL

October 20th 2016

Patients with chronic lymphocytic leukemia have an increased likelihood of developing secondary cancers and other diseases, often based on their age and gender.

Dr. Jan A. Burger on Role of MRD-Negativity in CLL

October 15th 2016

Jan A. Burger, MD, PhD, associate professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD)-negativity in chronic lymphocytic leukemia (CLL).

Venetoclax Receives Positive CHMP Opinion for CLL

October 15th 2016

The Committee for Medicinal Products for Human Use has recommended approval of venetoclax for the treatment of patients with chronic lymphocytic leukemia who have a 17p deletion (del[17p]) or TP53 mutation and are not good candidates for or have failed on a B-cell receptor pathway inhibitor. The potential indication would also be for patients who do not harbor the deletion or mutation but have progressed on both a BCR inhibitor and chemoimmunotherapy.

Dr. William Wierda on Role for Ibrutinib in Frontline CLL

October 3rd 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

Ibrutinib or FCR: Wierda Discusses First-Line Options for CLL

October 2nd 2016

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.